Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension

被引：1
|
作者：
Tocci, Giuliano [1 ,2 ]
机构：
[1] Univ Rome Sapienza, Dept Clin & Mol Med, St Andrea Hosp, Rome, Italy
[2] IRCCS Neuromed, Pozzilli, Italy
来源：
CARDIOLOGY | 2020年 / 145卷 / 09期
关键词：
ANGIOTENSIN-II RECEPTOR; NEPRILYSIN; GUIDELINES; ALISKIREN; INHIBITOR;
D O I：
10.1159/000508345
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：599 / 600
页数：2
相关论文
共 50 条
  • [41] Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects
    Flarakos, Jimmy
    Du, Yancy
    Bedman, Timothy
    Al-Share, Qusai
    Jordaan, Pierre
    Chandra, Priya
    Albrecht, Diego
    Wang, Lai
    Gu, Helen
    Einolf, Heidi J.
    Huskey, Su-Er
    Mangold, James B.
    XENOBIOTICA, 2016, 46 (11) : 986 - 1000
  • [42] First derivative emission spectrofluorimetric method for the determination of LCZ696, a newly approved FDA supramolecular complex of valsartan and sacubitril in tablets
    Ragab, Marwa A. A.
    Galal, Shereen M.
    Korany, Mohamed A.
    Ahmed, Aya R.
    LUMINESCENCE, 2017, 32 (08) : 1417 - 1425
  • [43] Prevention of Progressive Worsening of Heart Failure Over Time With The Angiotensin-receptor Neprilysin Inhibitor Sacubitril/valsartan (lcz696)
    McMurray, John
    Jhund, Pardeep
    Gong, Jianjian
    Rouleau, Jean
    Lefkowitz, Martin
    Desai, Akshay
    Rizkala, Adel
    Shi, Victor
    Swedberg, Karl
    Zile, Michael
    Solomon, Scott
    Packer, Milton
    CIRCULATION, 2015, 132
  • [44] Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials (vol 145, pg 589, 2020)
    Geng
    CARDIOLOGY, 2021, 146 (02) : 272 - 272
  • [45] Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model
    Lin, Wen
    Ji, Tao
    Einolf, Heidi
    Ayalasomayajula, Surya
    Lin, Tsu-Han
    Hanna, Imad
    Heimbach, Tycho
    Breen, Christopher
    Jarugula, Venkateswar
    He, Handan
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (05) : 1439 - 1451
  • [46] Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens
    Senni, Michele
    McMurray, John J. V.
    Wachter, Rolf
    McIntyre, Hugh F.
    Reyes, Antonio
    Majercak, Ivan
    Andreka, Peter
    Shehova-Yankova, Nina
    Anand, Inder
    Yilmaz, Mehmet B.
    Gogia, Harinder
    Martinez-Selles, Manuel
    Fischer, Steffen
    Zilahi, Zsolt
    Cosmi, Franco
    Gelev, Valeri
    Galve, Enrique
    Gomez-Doblas, Juanjo J.
    Nociar, Jan
    Radomska, Maria
    Sokolova, Beata
    Volterrani, Maurizio
    Sarkar, Arnab
    Reimund, Bernard
    Chen, Fabian
    Charney, Alan
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (09) : 1193 - 1202
  • [47] LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD
    Jing, Wanghui
    Vaziri, Nosratola D.
    Nunes, Ane
    Suematsu, Yasunori
    Farzaneh, Ted
    Khazaeli, Mahyar
    Moradi, Hamid
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (12): : 5473 - 5484
  • [48] Efficacy of LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in obese and overweight subjects with hypertension
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 65 - 65
  • [49] Comparative efficacy of valsartan and LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in hypertensive individuals: effects of gender
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 571 - 571
  • [50] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor (vol 56, pg 1461, 2017)
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    CLINICAL PHARMACOKINETICS, 2018, 57 (01) : 105 - 123
12345